Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma.
about
The evolving role of response-adapted PET imaging in Hodgkin lymphomaHodgkin lymphoma, version 2.2015.Advanced hodgkin lymphoma: a new era of therapy.Hodgkin disease-an ever-evolving therapy.Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and CaveatsPrognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography.Tailored strategies for radiation therapy in classical Hodgkin's lymphoma.Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma.FDG-PET/CT based response-adapted treatment.CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma.State-of-the-Art Research on "Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response".The role of PET in Hodgkin's lymphoma and its impact on radiation oncology.Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses.PET Response-Guided Treatment of Hodgkin's Lymphoma: A Review of the Evidence and Active Clinical TrialsReport of satellite workshop on interim-PET in Hodgkin lymphoma: 8th International Symposium on Hodgkin Lymphoma, Cologne, 23 October 2010.PET/CT adapted therapy in Hodgkin disease: current state of the art and future directions.Advances in oncologic imaging: update on 5 common cancers.[¹⁸F]fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography imaging in oncology: initial staging and evaluation of cancer therapyThe use of interim (18)F-fluorodeoxyglucose PET to guide therapy in lymphoma.Current role of FDG PET/CT in lymphoma.Management and controversies of classical Hodgkin lymphoma in pregnancy.Risk-adapted strategies for the treatment of Hodgkin lymphoma.PET-directed therapy in Hodgkin lymphoma: Ready for prime time?Comparison of the efficiency of ABVD versus BEACOPP for Hodgkin lymphoma treatment: a meta-analysis.De-escalation chemotherapy and hematological profiles in patients with advanced Hodgkin's lymphoma.Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors.Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in mantle cell lymphoma?The Gordian knot of interim 18-fluorodeoxyglucose positron emission tomography for Hodgkin lymphoma: a meta-analysis and commentary on published studies.Interim PET-CT may predict PFS and OS in T-ALL/LBL adult patients.The management of hodgkin lymphomas in pregnancies.Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.A 10-year experience with treatment of high and standard risk Hodgkin disease: six cycles of tailored BEACOPP, with interim scintigraphy, are effective and female fertility is preserved.
P2860
Q26750993-C6EF6E32-CDDC-4B51-9852-60AD8D7BA3C6Q30769157-EA8EBF35-525D-4CAF-A5E1-4A3721EBDF53Q34194160-FD0144A8-D63F-48FE-BA9A-4D184F76809CQ34463426-9A4DEE1F-55B9-465B-BCA7-E7E0BF4E1D45Q34475763-8AD78361-410F-438C-8912-7FB724E76C42Q34495333-E818A4CC-1497-41E1-9EDE-E16672741B4CQ34610653-DDEBF9B1-5CDE-4883-B0CF-EC359871ADF6Q35232775-04C08B58-973D-44A6-B75B-C6C0650E9336Q36286595-3FD8996B-29AE-4527-A9E4-A5BBEF90C26AQ36706850-70A20F2E-E1CF-4B70-B59F-F3B71C761C24Q37144956-44B3C1B3-F16B-4A58-9342-8B19DD3BF256Q37788240-58CA9665-92BE-4CF2-A095-E1677686FFE3Q37821961-22D9270E-BBD8-4CB8-9221-D9FB01ED52BFQ37828408-3F315559-7F7F-4089-89D2-66AEE30FEED1Q37857870-15DF7182-3DBE-432D-875A-89F6CB316A36Q38018865-B74CE5AF-1578-467D-AB7A-9A06C5FFA7B4Q38052458-FFAD484D-2383-45D0-A041-6DD03F99752CQ38077874-9332F95A-D194-4084-BE0F-D9B2530EF291Q38110318-C1D11CD3-7092-4F95-9CEE-A5C831263090Q38187365-6A150933-E6D0-4BD2-9DA2-B849DD76A85EQ38356460-1F129FE5-5155-4AC1-A204-D26F2D20B8B4Q38591137-E1D363E0-919B-4E48-8AA6-AD47F3B9059BQ38608555-8D15228A-8A37-4A28-9934-E4B3DCEA43CBQ38929198-8988EDA3-430A-4840-9AC4-79DF172F7E4DQ40499200-20DF7191-1DD8-4306-9602-F123642F88FDQ42287385-7AA59565-C473-45CA-9371-DD9E31B2DDFCQ44993089-E8BA0F6B-5978-45D4-B069-497C2988A8D3Q45428337-065E3BAD-864D-465E-89A2-E5053D72F05CQ47788594-9A91BDFD-9F53-446C-B5AA-B30E48F4E7E7Q48162570-FD9CB130-A60E-4378-8313-E71614DAFC82Q51037023-A780CDD8-4ACF-403C-BC75-D62528CB1474Q51408117-02065D44-74AB-46B7-A648-DCAD6C0B5E73
P2860
Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Two cycles of escalated BEACOP ...... high-risk Hodgkin's lymphoma.
@en
Two cycles of escalated BEACOP ...... high-risk Hodgkin's lymphoma.
@nl
type
label
Two cycles of escalated BEACOP ...... high-risk Hodgkin's lymphoma.
@en
Two cycles of escalated BEACOP ...... high-risk Hodgkin's lymphoma.
@nl
prefLabel
Two cycles of escalated BEACOP ...... high-risk Hodgkin's lymphoma.
@en
Two cycles of escalated BEACOP ...... high-risk Hodgkin's lymphoma.
@nl
P2093
P356
P1433
P1476
Two cycles of escalated BEACOP ...... high-risk Hodgkin's lymphoma.
@en
P2093
A Polliack
G Perez-Avraham
I Ben-Bassat
P304
P356
10.1093/ANNONC/MDP271
P577
2009-07-16T00:00:00Z